News Wire

A new-generation DNA-based Zika vaccine demonstrated both safety and ability to elicit an immune response against Zika in humans in a phase 1 clinical trial conducted through a partnership among the Perelman School of Medicine at the University of Pennsylvania, Inovio Pharmaceuticals, GeneOne Life Science,…
A U.S. appeals court has thrown out a ban on the sale of the cholesterol-lowering drug alirocumab (Praluent, Sanofi SA/Regeneron Pharmaceuticals) and ordered a new trial in the case that led to the ban, Reuters reports. The ruling from the U.S. Court of Appeals for the Federal Circuit in Washington,…
Scientists have pioneered a method to detect antibiotic susceptibility for urinary tract infections in less than 30 minutes, potentially enabling patients to be diagnosed and prescribed effective treatments during a single clinical visit. Urinary tract infections account for almost 8 million primary…
Breast cancer mortality rates dropped by 39% from 1989 through 2015, according to a study in CA: A Cancer Journal for Clinicians. Researchers estimate that 322,600 deaths were averted as a result. The declines were attributed to increased mammography screenings and better treatments. There is still…
Twelve cancers associated with obesity increased by 7% from 2005 to 2014, according to the CDC. They accounted for 40% of all cancer diagnoses in 2014, although the overall rate of new cancer diagnoses started falling in the 1990s. The 12 cancers associated with obesity are: adenocarcinoma of the esophagus,…
The FDA has approved Mylan's glatiramer acetate injection, the generic version of Copaxone (Teva) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Mylan will begin shipping imminently. Mylan's abbreviated new drug applications (ANDAs) were approved for two versions of glatiramer…
A seasonal flu vaccine that would be the first in the world to fight all types of the virus will be tested by British researchers in a two-year clinical trial involving more than 2,000 patients. The so-called universal vaccine was developed by Oxford University’s Jenner Institute and Vaccitech, a…
Overweight and obesity are associated with increased risk of 13 types of cancer that accounted for about 40% of all cancers diagnosed in the United States in 2014, according to the latest Vital Signs report by the Centers for Disease Control and Prevention (CDC). Overall, the rate of new cancer cases…
Itraconazole inhalation powder (Pulmazole [also known as PUR1900], Pulmatrix), a drug candidate for treating fungal infections in the lungs, has been designated as a qualified infectious disease product (QIDP) in a second indication by the FDA. Under the QIDP program, which is designed to speed the…
Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for depression and anxiety but their superiority over placebo has been questioned, generating considerable debate among researchers and clinicians. In a new study, Uppsala University researchers show that the way in which the treatment…
Health care experts have long known the benefits of integrated sepsis care programs, yet less information has been published on potential unintended consequences of these programs. That’s changed with a new study that suggests that electronic sepsis screenings and treatment protocols could, in fact,…
FDA chief Scott Gottlieb called for help from the insurance and PBM industries in August, asking them to play a part in solving the opioid crisis, the deadliest drug overdose crisis in American history. Gottlieb called for a meeting in September. That meeting took place September 6, but the FDA is downplaying…
The FDA has announced what its commissioner called “a major new set of policies” aimed at making it easier to bring generic competition to a category of branded medications known as complex drugs. Such products include high-cost medicines like metered-dose asthma inhalers and some injectable drugs,…
The FDA has granted a breakthrough therapy designation to brentuximab vedotin (Adcetris, Seattle Genetics, Inc.) in combination with chemotherapy for the firstline treatment of patients with advanced classical Hodgkin’s lymphoma. Positive topline results of the phase 3 ECHELON-1 clinical trial were…
Merck has become the latest pharmaceutical company to abandon development of potential new treatments for hepatitis C virus (HCV) infection in an increasingly crowded market. Merck elected to discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/ uprifosbuvir)…

Pages